Clinical Trials Logo

Neurologic Manifestations clinical trials

View clinical trials related to Neurologic Manifestations.

Filter by:

NCT ID: NCT01283087 Completed - Clinical trials for Transient Neurologic Symptoms

Spinal Anesthesia Using Lidocaine and Sufentanil and (Transient Neurological Symptoms) TNS

Start date: January 2011
Phase: N/A
Study type: Observational

The purpose of this study is to find out whether patients receiving spinal anesthesia containing lidocaine and sufentanil get transient neurological symptoms.

NCT ID: NCT00586638 Completed - Clinical trials for Neurologic Manifestations

Training Cognitive Control Processes in Older Adults

Start date: December 2007
Phase: N/A
Study type: Interventional

Control processes are classes of brain activity that initiate, coordinate, synchronize, and regulate elemental cognitive functions for the conduct of goal-directed behavior. The proposed research investigates whether exposure to a computer-based training protocol designed to enhance cognitive control processes will improve cognitive performance in healthy older adults.

NCT ID: NCT00478517 Withdrawn - Clinical trials for Spinal Trauma With Neurological Deficit

TETRAM 2. Treatment With Erythropoetin in Patients With Spinal Trauma With Neurological Deficit, Maximum Tolerated Dose Study

TETRAM2
Start date: May 2007
Phase: Phase 1
Study type: Interventional

The social, psychological, economic burden of Spinal trauma with deficit is great, and there is no curative treatment. Erythropoetin (EPO) is promising, due to its neuroprotective effects demonstrated in vitro, in vivo in animal models and in a preliminary study including patients with stroke. The study primary end point is to find out the maximum tolerated dose of EPO. This is based on the occurrence of pulmonary embolism during a 14 day delay following EPO injection. Secondary end points include comparisons of EPO kinetics in blood and cerebrospinal fluid (CSF), study of EPO effects on several inflammatory and apoptotic bio markers and blood cell counts. The experimental design is a dose scale study (600 to 2400 UI/Kg), using a single dose of rHuEPO, (EPREX®). The EPO dose is defined using a Bayesian continuous reassessment Method (CRM). The sample size is expected for less than 20 patients. Eligible patients are patients aged 15 to 65 years, able to receive the EPO injection within 12 hours of a spinal trauma, without vital blood loss or associated diseases. The follow-up lasts 6 months.

NCT ID: NCT00276380 Completed - Stroke, Acute Clinical Trials

A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke

Start date: February 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of Tanakan® 240mg in association with Acetylsalicylic acid (325mg/day) in the recovery of neurological impairment following ischemic stroke.

NCT ID: NCT00137527 Terminated - Clinical trials for Neurological Manifestations

Brain Oxygenation Monitoring in Patients Undergoing Coronary Artery Bypass Surgery

Start date: February 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether intraoperative brain oxygenation monitoring in cardiac surgery patients is effective in reducing postoperative neurologic and neurocognitive dysfunction.

NCT ID: NCT00123539 Terminated - Clinical trials for Cardiovascular Diseases

Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery

Start date: June 2001
Phase: N/A
Study type: Interventional

The purpose of this study is to test whether perioperative estrogen replacement in postmenopausal women reduces the risk for neurologic injury after coronary artery bypass graft (CABG) surgery.

NCT ID: NCT00070681 Completed - Clinical trials for Cardiovascular Diseases

Outcomes of Sleep Disorders in Older Men

Start date: September 2003
Phase: Phase 3
Study type: Observational

To determine the effects of sleep disorders on cardiovascular function and disease in older men.

NCT ID: NCT00041392 Completed - Clinical trials for Cardiovascular Diseases

Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery

POINT
Start date: December 2001
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine the effects of supplemental magnesium on the neurocognitive function of individuals undergoing coronary artery bypass graft (CABG) surgery.

NCT ID: NCT00037310 Completed - Hypertension Clinical Trials

New CVD Risk Factors for Lowered Cognitive Functioning

Start date: April 2001
Phase: N/A
Study type: Observational

To explore the associations between cognitive functioning and three major cardiovascular disease risk factors: high blood pressure; high total plasma homocysteine (tHcy); and ApoE e4 genotype.

NCT ID: NCT00007397 Completed - Clinical trials for Cardiovascular Diseases

Age, Risk Factors for CVD and Cognitive Functioning

Start date: February 2000
Phase: N/A
Study type: Observational

To relate cardiovascular disease (CHD) risk factors to cognitive performance among middle-aged and elderly men and women over a 10 year longitudinal study period.